← Leaderboards
Matthew L Freedman
Dana-Farber Cancer Inst
$13,331,420
Attributed
$24,491,662
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,496,698 · 14
By mechanism
R01$22,144,009 · 9
U19$21,005,036 · 2
P50$1,939,395 · 2
R21$408,258 · 1
Top collaborators
- Douglas Frederick Easton10 shared
- Christopher Alan Haiman10 shared
- J. Keith Joung10 shared
- Simon Andrew Gayther9 shared
- Paul Pharoah6 shared
- Mark M. Pomerantz6 shared
- Habibul Ahsan5 shared
- Myles A Brown5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Tracy T Batchelor$27,819,477
- Mark M. Pomerantz$1,781,713
- David A Barbie$12,794,638
- Alexander Gimelbrant$6,924,929
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesMapsGeneticMalignant Neoplasm Of ProstateVariantGenomeGenome Wide Association StudyPathway InteractionsCancer RiskRisk VariantGenetic VariantBiologyTraitRegulatory ElementGenome EditingAffectProstateAutomobile DrivingAllelesMalignant NeoplasmsCell LineGenetic Risk FactorGene ExpressionInnovation
Grant awards (56)
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies$1,347,915
R01 · FY2025 · CA · contact PI
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches$675,104
R01 · FY2025 · CA · contact PI
Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making$627,474
R01 · FY2025 · CA · contact PI
Developmental Research Program$209,314
P50 · FY2025 · CA · contact PI
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches$641,090
R01 · FY2024 · CA · contact PI
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies$640,260
R01 · FY2024 · CA · contact PI
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci$599,202
R01 · FY2024 · CA
Developmental Research Program$294,324
P50 · FY2024 · CA · contact PI
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches$661,392
R01 · FY2023 · CA · contact PI
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies$660,477
R01 · FY2023 · CA · contact PI
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci$622,687
R01 · FY2023 · CA
Developmental Research Program$249,075
P50 · FY2023 · CA · contact PI
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies$693,457
R01 · FY2022 · CA · contact PI
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci$668,422
R01 · FY2022 · CA
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches$660,909
R01 · FY2022 · CA · contact PI
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches$713,783
R01 · FY2021 · CA · contact PI
Functional Effects of Ovarian Cancer Risk Variants$612,989
R01 · FY2021 · CA
Functional Effects of Ovarian Cancer Risk Variants$618,508
R01 · FY2020 · CA
Identifying causal variants and genes underlying breast cancer risk loci$596,487
R01 · FY2020 · CA · contact PI
Functional Effects of Ovarian Cancer Risk Variants$598,208
R01 · FY2019 · CA
Identifying causal variants and genes underlying breast cancer risk loci$583,645
R01 · FY2019 · CA · contact PI
Defining the epigenetic landscape in human prostate cancer$582,787
R01 · FY2019 · CA · contact PI
Functional Effects of Ovarian Cancer Risk Variants$622,079
R01 · FY2018 · CA
Identifying causal variants and genes underlying breast cancer risk loci$606,904
R01 · FY2018 · CA · contact PI
Defining the epigenetic landscape in human prostate cancer$600,812
R01 · FY2018 · CA · contact PI
Functional Effects of Ovarian Cancer Risk Variants$149,945
R01 · FY2018 · CA
Functional Effects of Ovarian Cancer Risk Variants$686,463
R01 · FY2017 · CA
Defining the epigenetic landscape in human prostate cancer$633,613
R01 · FY2017 · CA · contact PI
Identifying causal variants and genes underlying breast cancer risk loci$611,136
R01 · FY2017 · CA · contact PI
Utilizing genetic and functional strategies to identify causal genes and alleles$484,483
R01 · FY2017 · GM · contact PI
Defining the epigenetic landscape in human prostate cancer$628,587
R01 · FY2016 · CA · contact PI
Identifying causal variants and genes underlying breast cancer risk loci$616,199
R01 · FY2016 · CA · contact PI
Utilizing genetic and functional strategies to identify causal genes and alleles$488,427
R01 · FY2016 · GM · contact PI
4C and Genome Editing for Causal SNP and Gene Discovery at Cancer Risk Loci$185,077
R21 · FY2016 · CA · contact PI
Defining the epigenetic landscape in human prostate cancer$628,587
R01 · FY2015 · CA · contact PI
Utilizing genetic and functional strategies to identify causal genes and alleles$520,107
R01 · FY2015 · GM · contact PI
4C and Genome Editing for Causal SNP and Gene Discovery at Cancer Risk Loci$223,181
R21 · FY2015 · CA · contact PI
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$574,120
U19 · FY2014 · CA
Utilizing genetic and functional strategies to identify causal genes and alleles$525,949
R01 · FY2014 · GM · contact PI
Elucidating Loci Involved in Prostate Cancer Suceptibility$457,500
U19 · FY2014 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,309,806
U19 · FY2013 · CA
Elucidating Loci Involved in Prostate Cancer Suceptibility$2,226,057
U19 · FY2013 · CA
Elucidating Loci Involved in Prostate Cancer Suceptibility$2,554,434
U19 · FY2012 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,486,910
U19 · FY2012 · CA
Elucidating Loci Involved in Prostate Cancer Suceptibility$2,539,039
U19 · FY2011 · CA
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,465,094
U19 · FY2011 · CA
P-2: Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus$262,259
P50 · FY2011 · CA · contact PI
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,738,466
U19 · FY2010 · CA
Elucidating Loci Involved in Prostate Cancer Suceptibility$2,653,610
U19 · FY2010 · CA
P-2: Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus$276,062
P50 · FY2010 · CA · contact PI
Fine mapping and characterization of the 8q24 prostate cancer risk locus$447,130
R01 · FY2009 · CA · contact PI
Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus$216,178
P50 · FY2009 · CA · contact PI
Fine mapping and characterization of the 8q24 prostate cancer risk locus$494,436
R01 · FY2008 · CA · contact PI
Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus$216,180
P50 · FY2008 · CA · contact PI
Fine mapping and characterization of the 8q24 prostate cancer risk locus$594,356
R01 · FY2007 · CA · contact PI
Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus$216,003
P50 · FY2007 · CA · contact PI